Search Results for "A-200"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for A-200. Results 171 to 180 of 181 total matches.

Drugs for Sexually Transmitted Infections

   
The Medical Letter on Drugs and Therapeutics • Jun 27, 2022  (Issue 1653)
or in breastfeeding women. 3. Delayed-release doxycycline (Doryx) 200 mg once daily for 7 days is as effective ...
This article includes recommendations for management of most sexually transmitted infections (STIs) other than HIV and viral hepatitis. Some of the indications and dosages recommended here have not been approved by the FDA (see Table 1).
Med Lett Drugs Ther. 2022 Jun 27;64(1653):97-104 |  Show IntroductionHide Introduction

Comparison Table: Some Lipid-Lowering Drugs (online only)

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
, 200 mg caps 30, 90 mg caps 200 mg PO once/day with food Renal impairment: Mild to moderate ...
View the Comparison Table: Some Lipid-Lowering Drugs
Med Lett Drugs Ther. 2022 Sep 19;64(1659):e152-6 |  Show IntroductionHide Introduction

Daridorexant (Quviviq) for Insomnia

   
The Medical Letter on Drugs and Therapeutics • Jul 11, 2022  (Issue 1654)
106.0 -24.2* -24.3* Placebo 71.8 -20.0 -19.9 108.1 -12.6 -14.0 * Statistically significant difference ...
The FDA has approved daridorexant (Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this indication; suvorexant (Belsomra) and lemborexant (Dayvigo) were approved earlier.
Med Lett Drugs Ther. 2022 Jul 11;64(1654):107-10 |  Show IntroductionHide Introduction

Suflave — A Low-Volume Colonoscopy Preparation

   
The Medical Letter on Drugs and Therapeutics • Sep 18, 2023  (Issue 1685)
24.90 23.70 39.10 Low-Volume PEG 3350-Based MoviPrep (Salix)9 generic 200 g PEG 3350 powder10 240 ...
The FDA has approved Suflave (Sebela/Braintree), a low-volume polyethylene glycol (PEG)- and sulfate-based product for cleansing of the colon prior to colonoscopy in adults. Other oral colonoscopy preparations available in the US are listed in Table 2. Suflave is marketed as tasting better than other products.
Med Lett Drugs Ther. 2023 Sep 18;65(1685):148-51   doi:10.58347/tml.2023.1685b |  Show IntroductionHide Introduction

Drugs for Treatment and Prevention of Venous Thromboembolism

   
The Medical Letter on Drugs and Therapeutics • Jul 25, 2022  (Issue 1655)
units SC q8-12h $651.00 Low-Molecular-Weight Heparins (LMWHs) Dalteparin – Fragmin (Pfizer) 200 IU/kg ...
Anticoagulants are the drugs of choice for treatment and prevention of deep venous thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE). US guidelines for treatment of VTE were updated in 2020 and 2021.
Med Lett Drugs Ther. 2022 Jul 25;64(1655):113-20 |  Show IntroductionHide Introduction

Lipid-Lowering Drugs

   
The Medical Letter on Drugs and Therapeutics • Sep 19, 2022  (Issue 1659)
, 200 mg caps 200 mg PO once/day24 24.00 Antara27 (Lupin) 30, 90 mg caps 90 mg PO once/day 507.90 ...
Cholesterol management guidelines from the American College of Cardiology/American Heart Association Task Force were last published in 2019.
Med Lett Drugs Ther. 2022 Sep 19;64(1659):145-52 |  Show IntroductionHide Introduction

Ozanimod (Zeposia) for Ulcerative Colitis

   
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021  (Issue 1633)
– Simponi (Janssen) 50 mg/0.5 mL, 100 mg/1 mL Induction: 200 mg SC at week 0, then 100 mg SC 12,113.30 auto ...
The oral sphingosine 1-phosphate (S1P) receptor modulator ozanimod (Zeposia – Bristol Myers Squibb) has been approved by the FDA for treatment of adults with moderately to severely active ulcerative colitis. It is the first S1P receptor modulator to be approved for treatment of ulcerative colitis. Ozanimod was approved in March 2020 for use in adults with relapsing forms of multiple sclerosis.
Med Lett Drugs Ther. 2021 Sep 20;63(1633):147-51 |  Show IntroductionHide Introduction

Drugs for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • Mar 20, 2023  (Issue 1672)
OnabotulinumtoxinA – 100, 200 unit powder 100 units (0.5 mL at 20 Urinary tract infection is common Botox (Allergan ...
In overactive bladder, involuntary bladder contractions due to detrusor overactivity result in urinary urgency, frequency, nocturia, and incontinence. The prevalence of the disorder increases with age. Nonpharmacologic treatment, including bladder training, urge suppression, pelvic floor muscle exercises, constipation management, modification of fluid intake, and avoidance of dietary irritants such as alcohol and caffeine, should be tried first.
Med Lett Drugs Ther. 2023 Mar 20;65(1672):41-5   doi:10.58347/tml.2023.1672a |  Show IntroductionHide Introduction

Adult Immunization

   
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022  (Issue 1661)
liver disease   16 10   13   RF RF HIV6 CD4 count ...
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Med Lett Drugs Ther. 2022 Oct 17;64(1661):161-8 |  Show IntroductionHide Introduction

Drugs for Irritable Bowel Syndrome

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
Dosage1 Cost2 Antibiotic Rifaximin – Xifaxan (Salix) 200, 550 mg tabs 550 mg tid x 14 days3 $2424.304 ...
Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating. IBS is classified by its predominant bowel symptom: constipation (IBS-C), diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U). Since the exact cause of IBS is unknown, the goal of treatment is symptom control. Some over-the-counter (OTC) products and prescription drugs for IBS are listed in Tables 1-4. The safety of these drugs during pregnancy and lactation is described in Table 5 (online only).
Med Lett Drugs Ther. 2025 Feb 3;67(1721):17-24   doi:10.58347/tml.2025.1721a |  Show IntroductionHide Introduction